CD44 recombinant protein is an important tool for cancer stem cell marker research and targeted drug development.

Author: Senior Product Manager of UA Views：10

CD44, also known as HCAM, PGP-1, and ECMR-III, is a transmembrane glycoprotein located on human chromosome 11 and a receptor for various ligands such as hyaluronic acid and osteopontin.

Recent Advances
Product Information

Recent Advances

CD44 Recombinant Protein Is an Important Tool for Cancer Stem Cell Marker Research and Targeted Drug Development

Brief Introduction: CD44, also known as HCAM, PGP-1, and ECMR-III, is a transmembrane glycoprotein located on human chromosome 11 and a receptor for multiple ligands such as hyaluronic acid and osteopontin. CD44 participates in cell adhesion, migration, lymphocyte homing, epithelial-mesenchymal transition, cancer stem cell maintenance, and metastasis regulation, and its standard form and variants exhibit complex functions in different tumors. Research on CD44 recombinant protein for ligand binding, antibody screening, receptor interaction, and functional validation can support tumor metastasis mechanism research, biomarker evaluation, and targeted drug development.

I. CD44 Is a Transmembrane Glycoprotein Receptor That Mediates Cell Adhesion and Microenvironmental Interactions.

CD44 is encoded by the CD44 gene on chromosome 11 and belongs to the type I transmembrane glycoprotein family, comprising an extracellular region, a transmembrane region, and an intracellular region. Its extracellular N-terminus can bind hyaluronic acid and can also interact with osteopontin, collagen, fibronectin, and matrix metalloproteinases, thereby mediating cell-cell and cell-extracellular matrix adhesion and signal transduction. CD44 is widely expressed in hematopoietic cells, epithelial cells, endothelial cells, and some stem cell populations, and plays important roles in lymphocyte activation, recirculation, homing, hematopoiesis, and tissue repair.

II. CD44 Forms Standard and Variant Isoforms Through Alternative Splicing, and Its Functions Are Isoform-Dependent.

CD44 transcripts can undergo complex alternative splicing, producing standard CD44s and multiple variant CD44v isoforms. CD44s lacks variable exons and is commonly found in various epithelial and hematopoietic cells; CD44v, on the other hand, inserts different variable exons near the membrane-proximal end of the extracellular region, such as v3, v5, v6, and v7-8, thereby altering ligand binding capacity, signaling complex assembly, and cell behavior. The functions of different isoforms in tumors are not entirely consistent: some variants are associated with tumor invasion, metastasis, and poor prognosis, while the standard form may also affect tumor growth, invasion, or therapeutic sensitivity under specific contexts.

III. CD44 Is a Marker of Multiple Cancer Stem Cells and Participates in Metastasis Regulation.

CD44 is widely used as a surface marker for cancer stem cells or tumor-initiating cells, especially in breast cancer, colorectal cancer, gastric cancer, liver cancer, non-small cell lung cancer, head and neck squamous cell carcinoma, and bladder cancer. For example, in breast cancer, the CD44high/CD24low cell population is often used to enrich cells with tumor-initiating capacity; in colorectal cancer, cervical cancer, and non-small cell lung cancer, expression of variants such as CD44v6 is associated with lymph node metastasis, liver metastasis, and shortened patient survival. CD44 can activate pathways such as FAK/Src, PI3K/Akt, and Wnt/β-catenin by binding hyaluronic acid, promoting epithelial-mesenchymal transition, cell migration, invasion, and tumor microenvironment remodeling.

IV. The CD44 Intracellular Fragment and Soluble Form Participate in Signal Transduction and Clinical Monitoring.

CD44 can undergo sequential cleavage by membrane-type matrix metalloproteinases and γ-secretase, producing an extracellular fragment, a transmembrane fragment, and an intracellular domain fragment. The CD44 intracellular domain can translocate to the nucleus and regulate gene transcription related to metastasis, survival, and stemness. In addition, soluble CD44 levels are elevated in the serum of some cancer patients and may be associated with tumor burden, metastasis risk, or disease progression, but its clinical interpretation requires careful judgment in combination with tumor type, detection method, and sample source.

V. CD44 Recombinant Protein Is a Key Reagent for Ligand Binding and Antibody Screening.

Because CD44 has multiple splice variants and glycosylation modifications, its natural conformation has an important impact on ligand binding and antibody recognition. CD44 recombinant protein can be used for hyaluronic acid binding assays, receptor-ligand interaction analysis, flow cytometry binding validation, SPR/BLI affinity determination, antibody specificity screening, establishment of positive cell detection systems, and functional research on CD44 signaling pathways. Selecting an expression system that preserves correct folding and glycosylation characteristics helps improve the reliability of antibody screening and mechanism research.

VI. CD44 Recombinant Protein Supports the Development of Targeted Antibodies, ADCs, and Drug Delivery Systems.

CD44 is highly expressed in various tumors, making it one of the important targets for antibody drugs, antibody-drug conjugates, bispecific antibodies, and targeted delivery systems. CD44 recombinant protein can be used for binding activity evaluation of candidate antibodies, epitope validation, receptor occupancy detection, positive tumor cell monitoring, establishment of biomarker methods, and specificity assessment of drug delivery vectors. Systematic functional validation of CD44 protein can provide upstream raw material support for tumor metastasis mechanism research and preclinical drug evaluation.

Conclusion

In response to CD44 target research and recombinant protein application needs, Univ provides CD44/CDw44/ECMR-III Fc Chimera Protein, Human. This product is suitable for CD44 antibody screening and characterization, receptor binding activity evaluation, establishment of flow cytometry detection systems, research on hyaluronic acid and osteopontin interactions, validation of cancer stem cell markers, and target functional assessment in the development of targeted drugs and delivery systems. By providing stable and reliable recombinant protein tools, Univ can provide technical support for CD44-related basic research and translational research.

CD44 recombinant protein is becoming an important tool connecting cancer stem cell biology, metastasis mechanism research, and targeted drug development. With further elucidation of CD44 isoform functions, signaling pathways, and clinical value, high-quality recombinant proteins will play an even more important role in antibody screening, receptor interaction analysis, biomarker validation, and preclinical evaluation.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next